NorthWest Biotherapeutics Inc (NWBO)

[hope4patients]

Published 8-4-2023:
“DC vaccines loaded with autologous tumor antigens can induce a potent immune response and are easy to achieve in individualized therapy for patients [84]. Nowadays, HybriCell and CreaVax-RCC have been approved for clinical practice, and a number of other DCs vaccines are in the stage of clinical trials. Among them, the DCVax-L vaccine is the most noticeable one since it significantly improves patients’ overall survival in both newly diagnosed and recurrent GBM in a recent study, which was the only one phase 3 clinical trial with a positive result ever reported in brain tumor immunotherapy.”

Cite: https://jnanobiotechnology.biomedcentral.com/articles/10.1186/s12951-023-02011-0